Strong Safety Profile[8,9]



RESET adverse event rates declined significantly over time due to clinical experience, commercial/ clinical data monitoring and the development of:

- Physician training protocols (device positioning and patient monitoring)
- Implant technique
- Troubleshooting guidelines

Risk only associated with implant period (indwell time); no long-term risks identified post removal.

FDA granted new Investigational Device Exemption (IDE)

To learn more, please visit **www.morphicmedical.com**

Ref Number	Description
1000630	RESET Combination System Packaged, Sterile
Contents Include:	
1000624	RESET™ Duodenal Implant and Delivery System, Packaged, Sterile
3000627	RESET™ Retrieval System, Packaged, Sterile

REFERENCES

1. Ryder et al. Benefits and Risks in 1101 Duodenal-Jejunal Bypass Liner (DJBL) Treated Patients. Presented at ADA. June 2024.
2. Gollisch et al. EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, 21 Dec 2016, 125(2):116-121)
3. Roehlen N et al. Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and metabolic Syndrome. International Federation for the Surgery of Obesity and Metabolic Disorders. Obesity Surgery 2020.
4. Ryder et al. Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the first National Health Service (NHS) EndoBarrier service. British Journal of Diabetes 2022.
5. Abu Dayyeh BK et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022 Aug 6;400(10350):441-451.
6. PMA P140008: FDA Summary of Safety and Effectiveness Data (SSED) for Obera IBG; 2015.
7. Jirapinyo P, Haas AP, Thompson CC. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes. Diabetes Care. 2018 May;41(5):1106-1115.
8. GI Dynamics, Inc. Internal Complaint Handling System: OUS data.
9. Aterburn et al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study, Annals of Internal Medicine, 4 December 2018.

The RESET System is intended to be used as an adjunct therapy to lifestyle and/or medication(s) for the management of morbid obesity and/or obesity in the presence of at least one concurrent cardiometabolic risk factor, e.g., type 2 diabetes and/or dyslipidemia. It is also intended to prevent contact of ingested nutrients with the mucosal lining of the duodenum and proximal jejunum (via the RESET Liner) in patients described above in order to promote weight loss, weight-loss mediated glycemic control and to minimize the likelihood of obesity-related complications such as cardiovascular disease and/ or deterioration of underlying type 2 diabetes.. The most commonly reported complications of RESET are gastrointestinal in nature. They include nausea, vomiting, and upper abdominal pain of mild to moderate severity and are mostly prevalent in the early days and weeks following Reset® placement. Uncommon risks include liver abscess, device-related bleeding, device migration, pancreatitis, or other infections, any of which may result in endoscopic or surgical removal of the device. As with all endoscopic and/or implant procedures, serious injury or death can occur.

CAUTION: Reset® is not approved for sale in the United States and is limited by Federal (US) Law to investigational use only.

Morphic Medical, Inc.
320 Congress Street, 3rd Floor
Boston, MA 02210
Tel: +49 30 40 50 45 33 10
customerservice@morphicmed.com

LA-0006 Rev C

morphic

RESET®

Endoscopic Device Therapy

Designed to help patients with obesity reduce the risk of cardiometabolic disorders.

morphic

Change Starts Within

RESET

RESET® provides patients living with cardiometabolic disorders such as type 2 diabetes, obesity and MASH/MAFLD with the only incision-free, endoscopic solution for immediate glycemic control and weight reduction, giving them the opportunity to change the course of their disease and improve their quality of life.



Multiple Cardiometabolic Health Improvements

TYPE 2 DIABETES

1.6% reduction in HbA1c demonstrates RESET as **highly effective in patients with refractory diabesity** with baseline HbA1c of ≥ to 7[1]

METABOLIC ASSOCIATED STEATOHEPATITIS

Patients with elevated liver stiffness at baseline (n=13) saw a **reduction of 7.1 kPa** with RESET[2]

CARDIOVASCULAR DISEASE

Estimated **overall CV risk decreased significantly** after RESET implantation and remained stable within 6 months after explantation[3]



77%

Long-term Sustainable Results

77% of patients with RESET maintained significant improvement 3 years after removal of the device.[4]

Satisfaction. For You and Your Patients.

Fully Reversible, Outpatient Procedure

- Delivered endoscopically through a 20 minute outpatient procedure
- Thin, flexible 60 cm sleeve (gastrointestinal liner) made of ePTFE
- Implanted within small intestine, extending through the duodenum and proximal jejunum
- Creates physical barrier between receptors in the intestinal wall and food and has been shown to directly affect key hormone levels
- Treatment with RESET may last up to 9 months and implant removal is conducted through an endoscopic outpatient procedure

Clinically Proven Weight Loss

Endoscopic Therapies offer a solution for patients living with obesity that do not qualify for bariatric surgery, or are looking for an alternative therapy that is reversible.

RESET has been shown to reduce total body weight at a higher rate than other endoscopic therapies.